Letters
Cardiovascular risk from drugs
Editor’s reply
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5390 (Published 29 September 2010) Cite this as: BMJ 2010;341:c5390
- Fiona Godlee, editor1
- 1BMJ, London WC1H 9JR, UK
- fgodlee{at}bmj.com
On the face of it, Keegan makes an interesting comparison.1 But on closer inspection the flaws in his logic are evident, to me at least.
Rosiglitazone is legal and non-addictive, and its production and supply are in the hands of one manufacturer. So too is most of the evidence of its benefits and harms. It was …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.